Introduction: Patient decision aids (PDAs) have been developed to help patients make an informed choice for a treatment option. Despite proven benefits, structural implementation falls short of expectations. The present study aims to assess the effectiveness and cost-utility of the PDA among newly diagnosed patients with localised prostate cancer and their partners, alongside implementation of the PDA in routine care.
Methods/analysis: A stepped-wedge cluster randomised trial will be conducted. The PDA will be sequentially implemented in 18 hospitals in the Netherlands, over a period of 24 months. Every 3 or 6 months, a new cluster of hospitals will switch from usual care to care including a PDA.The primary outcome measure is decisional conflict experienced by the patient. Secondary outcomes comprise the patient's quality of life, treatment preferences, role in the decision making, expectations of treatment, knowledge, need for supportive care and decision regret. Furthermore, societal cost-utility will be valued. Other outcome measures considered are the partner's treatment preferences, experienced participation to decision making, quality of life, communication between patient, partner and health care professional, and the effect of prostate cancer on the relationship, social contacts and their role as caregiver. Patients and partners receiving the PDA will also be asked about their satisfaction with the PDA.Baseline assessment takes place after the treatment choice and before the start of a treatment, with follow-up assessments at 3, 6 and 12 months following the end of treatment or the day after deciding on active surveillance. Outcome measures on implementation include the implementation rate (defined as the proportion of all eligible patients who will receive a PDA) and a questionnaire for health care professionals on determinants of implementing an innovation.
Ethics And Dissemination: This study will be conducted in accordance with local laws and regulations of the Medical Ethics Committee of VU University Medical Center, Amsterdam, The Netherlands. The results from this stepped-wedge trial will be presented at scientific meetings and published in peer-reviewed journals.
Trial Registration: Nederlands Trial Register NTR TC5177, registration date: May 28 2015.Pre-results.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5640129 | PMC |
http://dx.doi.org/10.1136/bmjopen-2016-015154 | DOI Listing |
Cancer Med
January 2025
College of Health Sciences, University of Bordeaux, Bordeaux, France.
Background: Prostate cancer is an example of the undervaluation of clinical examinations in care of patients. After external radiotherapy, cancer recurrence is primarily determined biologically by measuring prostate-specific antigen concentration. Consequently, there is no systematic requirement for the digital rectal examination (DRE).
View Article and Find Full Text PDFFront Mol Neurosci
December 2024
Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, United States.
Introduction: The prostate is densely innervated like many visceral organs and glands. However, studies to date have focused on sympathetic and parasympathetic nerves and little attention has been given to the presence or function of sensory nerves in the prostate. Recent studies have highlighted a role for sensory nerves beyond perception of noxious stimuli, as anterograde release of neuropeptides from sensory nerves can affect vascular tone and local immune responses.
View Article and Find Full Text PDFJ Cancer
January 2025
Department of Radiation Oncology, Nanyang Central Hospital, Nanyang, Henan, 473005, China.
Although single-fraction high-dose-rate brachytherapy (SFHDR-BT) for localized prostate cancer has been attempted in clinical trials, there is currently a lack of relevant medical evidence. It is essential to conduct a systematic analysis of the long-term safety and efficacy of SFHDR-BT. Comprehensive and systematic searches for eligible studies were performed in PubMed, Embase, and the Cochrane Library databases.
View Article and Find Full Text PDFBJUI Compass
December 2024
USC Institute of Urology, Catherine and Joseph Aresty Department of Urology, Keck School of Medicine University of Southern California Los Angeles California USA.
Objective: To assess the carbon footprint, accessibility, and diagnostic performance of an expedited 'One-Stop' prostate cancer (PCa) diagnostic pathway.
Materials And Methods: A total of 1083 consecutive patients undergoing magnetic resonance imaging (MRI) followed by transrectal ultrasound fusion-guided prostate biopsy (PBx) were identified from a prospective database. The patients were divided according to the diagnostic pathway: One-Stop, with MRI and same-day PBx (3 hours apart), or Standard, with MRI followed by a second visit for PBx.
Objectives: We aim to determine the prognostic significance of DNA methylation () in two independent prostate cancer cohorts with long-term clinical follow-up data.
Subjects/patients And Methods: We first re-examined a published, in-house whole genome bisulphite sequencing (WGBS) prostate cancer dataset, derived from radical prostatectomy (RP) tissue ( = 15) with median follow-up 19.5 years, to confirm and visualise the association between and patient mortality.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!